Clinical Trial Update: Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency. [Phase 4]

View source ↗

Summary

This is a Phase 4 extension study of intravenous Zemaira in subjects with emphysema due to alpha-1 antitrypsin deficiency; results from the completed trial were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Emphysema

Drugs mentioned

• Zemaira (human alpha-1 proteinase inhibitor)

Snippet

Sponsor: CSL Behring | Conditions: Emphysema, Alpha 1-proteinase Inhibitor Deficiency | Phase 4 | Status: COMPLETED | Results posted: 2016-07-12